During COP30, held on the edge of the Amazon rainforest, one of the most heated debates concerned the significance of the Amazon for the planet. It covers just 1.3% of the Earth’s total surface area, or 7% of its land area — yet its ecological importance is beyond dispute: 50% of the world’s biodiversity and 20% of all freshwater on the planet. That is an enormous function for little more than 1% of the Earth.
The pancreas presents a similar paradox. It accounts for less than 0.1% of the human body’s total weight, measuring between 15 and 25 cm in length and weighing an average of 60 to 100 grams. It fits in the palm of a hand, and yet it is capable of determining the fate of an entire life and of tying medicine into its greatest knot. Small in size and colossal in importance, the pancreas harbors, among so many challenges, a particularly daunting piece of genetic machinery — or rather, a heavy-calibre weapon: the K-RAS gene. Its trigger can fire one of the most lethal cancers known to humankind.
Pancreatic cancer ranks among the most feared diagnoses in medicine: silent, aggressive, and associated with some of the lowest survival rates in oncology. Physicians feel powerless before this malignancy. It bears an uncanny resemblance to a UFO bombarding the earth.
And then ASCO (the American Society of Clinical Oncology) launched a stunning broadside from Chicago to seize the attention of the scientific world: Daraxonrasib, whose new results demonstrated disease control and doubled survival in advanced cases. A single tablet capable of silencing the executioner K-RAS gene. Applause was not lacking after the announcement of the research findings. Not the ceremonial kind, nor the polite enthusiasm of the moment, nor frenzied shouts of “woo-hoo.” Had it been a concert, it would have been the unanimous “Bravo, Bravo!” with everyone on their feet. Perhaps that is why those resonant palms echoed across the entire planet — not merely through social media, but in headlines in the world’s leading publications. There was a collective sense that something important was happening. It was a spark in oncology, after decades in which this malignancy had come to symbolize, and still represents, one of medicine’s greatest challenges. The research results proved capable of shifting perspectives that until then had seemed firmly entrenched.
We can thus say that K-RAS has finally met its match — the compound that can pull it from the socket. Its name is even difficult to pronounce: Daraxonrasib, which will no doubt be shortened to Daraxon, or simply Dara, in oncological circles. Even without representing a cure, it is fiat lux in the darkness of oncology; it is hope, it is science — and emphatically not a miracle.
For those outside the medical field, some context is in order: the ASCO congress is the world’s foremost oncology gathering. It is there that the most relevant advances in cancer diagnosis and treatment are typically presented. It is not an environment known for euphoria. Scientists are trained to distrust their own results, to question others’ conclusions, and to celebrate each achievement with measured caution. Among those present was Clarissa Baldotto, a member of GBOT (Brazilian Thoracic Oncology Group), who focuses on lung cancer and was positively radiant: “just to think that there could be prospects for other tumors carrying the same type of mutation.” The “other” in question is lung cancer.
Even if it is a small step for medicine, it was a gain in hope that blossomed within the small pancreas, defying all logic of proportions.
Perhaps nature is constantly trying to teach us that greatness is not measured in hectares, centimetres, or grams — but in impact… in applause. And the pancreas fits in the palm of a hand.
Yes, we need more COPs, just as we need more ASCOs. After all, the future tends to begin in places few perceive — but which sustain the balance… Because every time science makes itself into light, all of humanity sees a little further ahead.
Jader Leite — Doctor in Hydraulic and Environmental Engineering, University of São Paulo (USP)
Roger Normando — Professor of Thoracic Surgery, Federal University of Pará (UFPA) and Member of GBOT (Brazilian Thoracic Oncology Group)
Article originally published in the newspaper “O Diário do Pará”
Nenhum comentário:
Postar um comentário